Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report
- 1 May 1995
- Vol. 45 (5) , 839-845
- https://doi.org/10.1016/s0090-4295(99)80092-2
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Use of Cyproterone Acetate in Prostate CancerPublished by Elsevier ,2021
- Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrolCancer, 1993
- Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigenCancer, 1993
- Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancerCancer, 1992
- The Clinical Usefulness of Serum Prostate Specific Antigen After Hormonal Therapy of Metastatic Prostate CancerJournal of Urology, 1992
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaNew England Journal of Medicine, 1989
- The Role of Prostate Specific Antigen as a Tumor Marker in Men with Advanced Adenocarcinoma of the ProstateJournal of Urology, 1989
- The Combination of Cyproterone Acetate and Low Dose Diethylstilbestrol in the Treatment of Advanced Prostatic CarcinomaJournal of Urology, 1988
- Relative Effectiveness of Alternative Androgen Withdrawal Therapies in Initiating Regression of Rat ProstateJournal of Urology, 1988
- Intermittent endocrine therapy for advanced prostate cancerCancer, 1986